As part of this planned transition, Robert Plenge will remain with Bristol Myers Squibb in an advisory capacity through March 2027 to support a seamless transition before departing the company.

Effective January 1, 2027, the unified R&D organization will bring together Bristol Myers Squibb’s scientific and clinical expertise as one organization, strengthening collaboration from discovery through development. By combining the strengths of its teams, BMS aims to advance its pipeline with greater speed, sharper focus and a shared commitment to delivering for patients.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.